KAYEXALATE, powder for suspension oral and rectal bottle, 454 g
Active ingredients: Sodium polystyrene sulfonate
Commercialized according to BDPMANSM noticeDispensing in France: Prescription only
Powder for suspensionbottle, 454 gorale;rectale
Supply disruption
Package details
Original BDPM fields are shown in French.
- Official name
- KAYEXALATE, poudre pour suspension orale et rectale
- Pharmaceutical form
- poudre pour suspension et
- Route of administration
- orale;rectale
- Presentation description
- 1 flacon(s) de 454 g
- Marketing authorisation holder
- PHARMA LAB
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 26 Dec 2024
- Prescription and dispensing conditions
- Prescription only
- List II: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62073400CIP74900478CIP133400949004782Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| SODIUM (POLYSTYRÈNE SULFONATE DE)poudre | 453,70036 g · une boite de 454 g | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.